IL17A and lung cancer: Drawing parallels with our work (1), from Figure 1C, we have demonstrated a range of cytokine induction (IL-10, IFNγ, TNFα, IL-17, IL-6 and IL-2) between healthy controls and Bregs taken from lung cancer patients who do and do not develop autoinflammatory sequelae post treatment with checkpoint blockade.